Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Christopher McPherson, Christine R Lockowitz, Jason G Newland
Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete passage of maternal immunity and a high degree of genetic variability within the virus contribute to morbidity and have also prevented successful neonatal vaccine development...
April 1, 2024: Neonatal Network: NN
#22
JOURNAL ARTICLE
Quang Luu Quoc, YeJi Kim, Gunwoo Park, Thi Bich Tra Cao, Youngwoo Choi, Yong Hwan Park, Hae-Sim Park
BACKGROUND: Neutrophilic asthma (NA) is a severe asthma phenotype associated with steroid resistance and IL-1β overproduction; however, the exact mechanism remains unclear. Moreover, the dysfunction of tumor necrosis factor-alpha signaling pathway, a regulator of IL-1β production, was associated with the deficiency of OTU deubiquitinase with linear linkage specificity (otulin) in autoimmune patients. OBJECTIVE: We hypothesized that otulin downregulation in macrophages (Mφ) could trigger Mφ activation via the nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 (NLRP3) inflammasome signaling pathway...
April 8, 2024: Journal of Allergy and Clinical Immunology
#23
REVIEW
Stefano Taddei, Nqoba Tsabedze, Ru-San Tan
β-blockers are a heterogeneous class, with individual agents distinguished by selectivity for β1 - vs. β2 - and α-adrenoceptors, presence or absence of partial agonist activity at one of more β-receptor subtype, presence or absence of additional vasodilatory properties, and lipophilicity, which determines the ease of entry the drug into the central nervous system. Cardioselectivity (β1 -adrenoceptor selectivity) helps to reduce the potential for adverse effects mediated by blockade of β2 -adrenoceptors outside the myocardium, such as cold extremities, erectile dysfunction, or exacerbation of asthma or chronic obstructive pulmonary disease...
2024: Current Medical Research and Opinion
#24
REVIEW
Hans-Peter Marti, Abel Alberto Pavía López, Pedro Schwartzmann
Cardioselective β-blockade is generally well tolerated in practice and contraindications to this therapy are uncommon. β-blockers are a diverse therapeutic class, and their individual tolerability profiles are influenced strongly by their pharmacodynamic effects across different adrenergic receptors. Bisoprolol, probably the β-blocker with the highest selectivity for blockade of β1 - vs. β2 -adrenoceptors, does not block β2 -adrenoceptors to an appreciable extent at doses in therapeutic use...
2024: Current Medical Research and Opinion
#25
Toshiyuki Sumi, Keito Suzuki, Yuta Koshino, Takumi Ikeda, Yuichi Yamada, Hirofumi Chiba
Allergic bronchopulmonary aspergillosis (ABPA) often necessitates treatment with systemic steroids and antifungals, which are associated with relapses and side effects. We report an 82-year-old woman with eosinophilic asthma, experiencing sputum production and dyspnea, who was diagnosed with ABPA based on her chest CT, pulmonary function tests, and elevated blood eosinophils and immunoglobulin E. Due to the presence of osteoporosis and diabetes, standard steroid therapy was considered a high risk. Instead, we administered dupilumab, an interleukin 4 receptor alpha (IL4-Rα) antibody targeting Th2 cytokine signaling...
March 2024: Curēus
#26
JOURNAL ARTICLE
Timothy M Buckey, Kathleen E Sullivan
No abstract text is available yet for this article.
April 7, 2024: Annals of Allergy, Asthma & Immunology
#27
JOURNAL ARTICLE
Mei Sheng Duh, Melissa H Roberts, Kieran J Rothnie, Wendy Y Cheng, Philippe Thompson-Leduc, Shiyuan Zhang, Alexandrosz Czira, David Slade, Alexandra Greatsinger, Adina Zhang, Douglas Mapel
INTRODUCTION: Despite adherence to inhaled corticosteroid/long-acting β2 -agonist (ICS/LABA) therapy, many patients with asthma experience moderate exacerbations. Data on the impact of moderate exacerbations on the healthcare system are limited. This study assessed the frequency and economic burden of moderate exacerbations in patients receiving ICS/LABA. METHODS: Retrospective, longitudinal study analyzed data from Optum's de-identified Clinformatics® Data Mart Database recorded between October 1, 2015, and December 31, 2019...
April 7, 2024: Respiratory Medicine
#28
JOURNAL ARTICLE
Christopher Alexander Hinze, Rainer Ehmann, Margret Jandl, Katrin Milger, Olaf Schmidt, Christian Schulz, Dirk Skowasch, Tobias Welte, Roland Buhl, Eckard Hamelmann, Marco Idzko, Christian Taube, Stephanie Korn, Hendrik Suhling
After the GINA update in 2019, the proportion of SMART therapy increased with evidence for better disease control in SMART patients compared to SABA alone https://bit.ly/3SSPX1C.
March 2024: ERJ Open Research
#29
JOURNAL ARTICLE
Tasmin Barry, Mark Holliday, Jenny Sparks, Rowan Biggs, Atalie Colman, Rebekah Lamb, Karen Oldfield, Nick Shortt, Kyley Kerse, John Martindale, Allie Eathorne, Michaela Walton, Bianca Black, Matire Harwood, Pepa Bruce, Ruth Semprini, Andrew Bush, Louise Fleming, Catherine A Byrnes, David McNamara, Lee Hatter, Stuart R Dalziel, Mark Weatherall, Richard Beasley
BACKGROUND: Asthma is the most common chronic childhood respiratory condition globally. Inhaled corticosteroid (ICS)-formoterol reliever-based regimens reduce the risk of asthma exacerbations compared with conventional short-acting β2 -agonist (SABA) reliever-based regimens in adults and adolescents. The current limited evidence for anti-inflammatory reliever therapy in children means it is unknown whether these findings are also applicable to children. High-quality randomised controlled trials (RCTs) are needed...
March 2024: ERJ Open Research
#30
JOURNAL ARTICLE
Ziwen Qin, Yujuan Chen, Na Liu, Yonggang Wang, Lili Su, Bin Liang, Chuanjun Huang
Background and purpose: The Bushenyiqi decoction (BYD), a contemporary prescription of traditional Chinese medicine (TCM), has been observed to significantly ameliorate asthma symptoms in patients based on clinical observations. Although multi-component and multi-target characteristics are important attributes of BYD treatment, its pharmacological effect on asthma and the underlying mechanism of action remain unclear. Method: Network pharmacology: the asthma-related genes were retrieved from the GeneCards and OMIM database...
2024: Frontiers in Pharmacology
#31
JOURNAL ARTICLE
Ying-Wen Su, Wen-Yu Huang, Sheng-Hsiang Lin, Po-Sheng Yang
OBJECTIVES: To evaluate the effects of Reishimmune-S, a fungal immunomodulatory peptide, on the quality of life (QoL) and natural killer (NK) cell subpopulations in patients receiving adjuvant endocrine therapy (ET) for breast cancer (BC). METHODS: Patients who received adjuvant ET for stage I-III hormone receptor-positive BC without active infection were enrolled in this prospective pilot study. Reishimmune-S was administered sublingually daily for 6 months...
2024: Integrative Cancer Therapies
#32
JOURNAL ARTICLE
Junling Wang, Mengmeng Zhan, Yaping Zhai, Siqin Wang, Fangqiu Gu, Zhuo Zhao, Zhaolong Zhang, Yifei Li, Xin Dong, Yijie Zhang, Bingyu Qin
Allergic asthma (AA) is closely associated with the polarization of T helper (Th)2 and Th17 cells. Interleukin (IL)-18 acts as an inducer of Th2 and Th17 cell responses. However, expressions of IL-18 and IL-18 receptor alpha (IL-18Rα) in blood Th2 and Th17 cells of patients with AA remain unclear. We therefore investigated their expressions in Th2 and Th17 cells using flow cytometric analysis, qPCR and murine AA model. We observed increased proportions of Th2, Th17, IL-18+, IL-18+ Th2 and IL-18+ Th17 cells in blood CD4+ T cells of patients with AA...
April 8, 2024: Clinical and Experimental Immunology
#33
JOURNAL ARTICLE
Ruisong Gong, Zihao Wang, Gang Tan, Yuguang Huang
BACKGROUND: Asthma, a principally T helper 2 (Th2) cell mediated immunological disease, is categorized into Th2-high and Th2-low endotypes. The influence of these endotypes on clinical characteristics and treatment responsiveness in asthma is yet to be completely understood. This study delves into the underlying molecular mechanisms of Th2 endotypes on asthma. METHODS: Transcriptomics data of airway epithelial and corresponding clinical information were sourced from the GEO...
April 15, 2024: Heliyon
#34
JOURNAL ARTICLE
Antonio Faraone, Alberto Fortini, Vanni Borgioli, Chiara Cappugi, Aldo Lo Forte, Valeria Maria Bottaro, Augusto Vaglio
BACKGROUND: eosinophilic granulomatosis with polyangiitis (EGPA) is a rare multisystem inflammatory disease characterized by asthma, eosinophilia and granulomatous or vasculitic involvement of various organs. While the eye is uncommonly affected in patients with EGPA, multiple ophthalmic manifestations have been reported, which can result in serious visual impairment without timely treatment. CASE REPORT: we report the case of a 79-year-old woman with a history of asthma and nasal polyps who presented with low-grade fever, mild alteration of mental status, and fatigue...
2024: European Journal of Case Reports in Internal Medicine
#35
JOURNAL ARTICLE
Jessica Gates, Andrew Hearn, Tom Mason, Mariana Fernandes, Linda Green, Louise Thomson, Cris Roxas, Jodie Lam, Grainne d'Ancona, Alexandra M Nanzer, Jaideep Dhariwal, David J Jackson
BACKGROUND: Dupilumab is an anti-IL4R monoclonal antibody (mAb) with proven efficacy in severe eosinophilic asthma (SEA). A suboptimal response to anti-IL5/5R mAbs is seen in some patients with ongoing evidence of T2 inflammation. OBJECTIVE: To understand whether targeting IL-13 pathways with dupilumab in these patients may lead to better clinical outcomes. METHODS: We performed a retrospective analysis of the extended clinical effectiveness of dupilumab up to 2 years of treatment in patients with SEA who had not responded adequately to anti-IL5/5R biologics...
April 5, 2024: Journal of Allergy and Clinical Immunology in Practice
#36
JOURNAL ARTICLE
Noé Garin, Borja Zarate-Tamames, Sonia Jornet, Eva María García, María Del Mar López-Gil, Gregorio Romero, Jorge Del Estal
OBJECTIVE: Respiratory diseases present a challenge for the healthcare system due to their prevalence and clinical impact. The aim of this study was to explore the current situation of hospital pharmacy in the field of respiratory diseases. METHOD: Observational, cross-sectional study, with a national scope, divided into 2 parts. In an initial phase, the activity and level of pharmaceutical care in respiratory diseases was evaluated through an online questionnaire using REDCap...
April 5, 2024: Farmacia Hospitalaria
#37
JOURNAL ARTICLE
Manuela Latorre, Angela Rizzi, Pierluigi Paggiaro, Ilaria Baiardini, Diego Bagnasco, Stefano DelGiacco, Carlo Lombardi, Vincenzo Patella, Eleonora Nucera, Roberta Parente, Giovanni Paoletti, Laura Pini, Erminia Ridolo, Gianenrico Senna, Francesco Blasi, Giorgio Walter Canonica, Arianna Aruanno, Carmen Ballacchino, Marco Bonavia, Cecilia Calabrese, Marco Caminati, Monica Carbonara, Cristina Cardini, Cristiano Caruso, Luciano Cattani, Maria Angiola Crivellaro, Alessandra Diana, Eugenia Durante, Elisabetta Favero, Maria Pia Foschino Barbaro, Sandra Frateiacci, Gabriella Guarnieri, Alessia Lofaro, Francesca Losa, Nadia Magarò, Francesco Menzella, Luisa Ricciardi, Giulia Scioscia, Elisa Testino, Francesca Torracca
OBJECTIVE: Patients' perceptions of asthma symptoms, and attitudes regarding diagnosis and management, can affect their ability to reach good asthma control. The aim of the study was to explore patients' perceptions of asthma management, with focus on treatment with oral corticosteroids (OCS). METHODS: A DOXAPHARMA survey was conducted. A questionnaire with 46 multiple choice questions was completed by 50 patients with severe uncontrolled asthma, and 258 with mild-moderate controlled or partly controlled asthma...
April 5, 2024: Journal of Asthma
#38
Subbarayudu Boda, Venkata Narayana Badipatla, Erramelli Nag Divya, Palak Dutta, Rohit Ganduboina
INTRODUCTION AND IMPORTANCE: Churg-Strauss syndrome (CSS) is a rare multisystemic condition characterized by asthma, blood and tissue eosinophilia, and vasculitis. The purpose of this work is to present a detailed overview of CSS, focusing on its epidemiology, clinical symptoms, histological criteria, gastrointestinal involvement, and therapy. CASE PRESENTATION: The authors report a case of a 40-year-old woman with CSS who had peripheral eosinophilia, small vessel vasculitis, and bronchial asthma...
April 2024: Annals of Medicine and Surgery
#39
Vaishnavi R Waghe, Lajwanti Lalwani, Priyanka K Chilhate
This study focuses on a 56-year-old male laborer who presented to the respiratory department with grade III dyspnea persisting for 20 days, aggravated in the mornings, accompanied by chest pain over the last two days. The patient reported a productive cough producing yellowish sputum for 15 days and an ongoing fever during this period. With a two-year medical history of seasonal bronchial asthma, the patient had been using an inhaler three times daily for the past month. Additionally, a 20-year history of smoking, averaging five cigarettes per day, was disclosed...
March 2024: Curēus
#40
JOURNAL ARTICLE
Frederik Trinkmann
BACKGROUND: Diagnostic and therapeutic options for asthma have improved with asthma control and remission being of central importance. The RELEVANT study aimed for a nationwide snapshot of current asthma diagnosis and treatment in general practice and specialty care for identification of further aspects for optimization. METHOD: RELEVANT is a nationwide cross-sectional study using a structured questionnaire. This comprised 14 questions on asthma-related topics covering diagnostics and therapy...
April 2024: MMW Fortschritte der Medizin
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
